DataString Consulting Company Logo
DataString Consulting Company Logo
Thioridazine Hci Tablets Market
Home»Recent Reports»Thioridazine Hci Tablets Market

Thioridazine Hci Tablets Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802547, Published - June 2025

Segmented in Dosage Form (Oral, Liquid Solution), Distribution Channel (Retail Pharmacy, Online Pharmacy, Hospital Pharmacy), Application, Prescription Type, Patient Population and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Thioridazine Hci Tablets
Market Outlook

The market, for Thioridazine Hci Tablets was estimated at $569.8 million in 2024; and it is anticipated to increase to $864.8 million by 2030 with projections indicating a growth to around $1.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.2% over the forecast period. The substantial growth trajectory visualized for Thioridazine HCI tablets can largely be attributed to its escalating relevance in the clinical space. Numerous health factors contribute to the augmented demand for this medication, including an upsurge in the prevalence of mental health disorders, heightened awareness about therapeutic options, and easier access to medical care. Accordingly, the consistent evolution of Thioridazine HCI tablets within the sphere of psychiatric treatment has established its current significance and ongoing relevance. Yet, the potential future of these tablets is not only solely determined by the present climate, but also heavily driven by the innovative advancements that exemplify this dynamic market.


Emphasizing its multifaceted role, Thioridazine HCI tablets stand out for their unique features and broad-spectrum applications. Acting as an antipsychotic medication, it successfully alleviates symptoms associated with schizophrenia and various related mental health conditions. As a testament to its versatility, new uses are continuously being explored, including potential utilization in neurodegenerative disorders.


Market Size Forecast & Key Insights

2019
$569M2024
2029
$1.1B2034

Absolute Growth Opportunity = $572M

The Thioridazine Hci Tablets market is projected to grow from $569.8 million in 2024 to $1.14 billion in 2034. This represents a CAGR of 7.2%, reflecting rising demand across Management of Schizophrenia, Treatment of Behavioral Problems in Children and Use in Psychoactive Drug Therapy.

The Thioridazine Hci Tablets market is set to add $572 million between 2024 and 2034, with manufacturer targeting Online Pharmacy & Hospital Pharmacy Distribution Channel projected to gain a larger market share.

With Growing demand for effective antipsychotic medication, and Influence of generic drugs on market pricing, Thioridazine Hci Tablets market to expand 100% between 2024 and 2034.

Opportunities in the Thioridazine Hci Tablets Market

Collaborative Strategies

Strategic collaborations are instrumental in shaping the growth trajectory of the Thioridazine HCl market.

Untapped Market Potential and Technological Advancements in Pharmaceutical Industry

Given the extensive use of Thioridazine HCl tablets in the field of psychopharmacology, the industry presents a vast market that remains largely untapped. Emerging economies, with their increasing focus on mental health, represent significant opportunities. Countries such as India, China, and Brazil are experiencing a surge in mental health awareness, paving the way for the greater acceptance and use of antipsychotic medications like Thioridazine HCl. As manufacturers explore these markets, the demand for Thioridazine HCI tablets is likely to increase, thus driving market growth.

Technological innovation in the pharmaceutical industry also provides significant opportunities for Thioridazine HCI tablets. The advent of novel drug delivery systems, improved formulation techniques, and advanced manufacturing technologies can enhance product efficacy, reduce side effects, and increase patient compliance. Such advancements can potentially widen the application scope of Thioridazine HCl, thus contributing to market expansion.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

Significant development is observed in the Asia-Pacific market for Thioridazine HCI tablets. This is largely attributed to the escalating incidence of mental disorders coupled with the ever-increasing population in this region. Market growth is highly inspired by stiff competition among local and international companies, resulting in affordable solutions for the populous market. Key market drivers include a broader recognition of mental health importance, improving healthcare infrastructure, and government support in promoting affordable access to medication. Local pharmaceutical companies engaging in the production of Thioridazine HCI tablets offer promising opportunities, particularly in emerging economies like India and China.

North America Outlook

The North American region demonstrates substantial market activity for Thioridazine HCI tablets. This market dominance is steered by advanced healthcare infrastructure, higher prevalence of mental disorders, and favorable health insurance policies that cover prescribed medication. Key players in this region engage in fierce competition, prompting innovative manufacturing and marketing strategies to gain a competitive edge. Drivers for this Thioridazine HCI tablets market include a rise in clinical studies, patient awareness programs, and the regional trend toward personalized medicine. The increasing government funding in the healthcare sector augments opportunities for market expansion and higher penetration of Thioridazine HCI tablets.

North America Outlook

The North American region demonstrates substantial market activity for Thioridazine HCI tablets. This market dominance is steered by advanced healthcare infrastructure, higher prevalence of mental disorders, and favorable health insurance policies that cover prescribed medication. Key players in this region engage in fierce competition, prompting innovative manufacturing and marketing strategies to gain a competitive edge. Drivers for this Thioridazine HCI tablets market include a rise in clinical studies, patient awareness programs, and the regional trend toward personalized medicine. The increasing government funding in the healthcare sector augments opportunities for market expansion and higher penetration of Thioridazine HCI tablets.

Asia-Pacific Outlook

Significant development is observed in the Asia-Pacific market for Thioridazine HCI tablets. This is largely attributed to the escalating incidence of mental disorders coupled with the ever-increasing population in this region. Market growth is highly inspired by stiff competition among local and international companies, resulting in affordable solutions for the populous market. Key market drivers include a broader recognition of mental health importance, improving healthcare infrastructure, and government support in promoting affordable access to medication. Local pharmaceutical companies engaging in the production of Thioridazine HCI tablets offer promising opportunities, particularly in emerging economies like India and China.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, UK, Japan, Canada are expected to grow at 4.7% to 6.9% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 8.3% to 9.9% CAGR

Market Analysis Chart

The global market for Thioridazine HCI tablets is marked by several notable drivers and restraints that directly influence its growth trajectory. Key market drivers for Thioridazine HCI tablets primarily include the rise in chronic mental health disorders, accelerating medical advancements, and an overall surge in pharmaceutical research and development activities. By tackling severe mental conditions like schizophrenia, these tablets have justified a significant demand in the healthcare sector.

Recent Developments and Technological Advancement

December 2024

Medical giant Pfizer expanded its mental health division with an increased manufacture of Thioridazine HCl tablets to meet the escalating global demand

September 2024

A study conducted by Mayo Clinic reported Thioridazine HCl tablets showing potential benefits in reducing symptoms of severe PTSD, opening new therapeutic opportunities

May 2024

Pharmaceutical leader Sanofi initiated a phase-3 clinical trial of Thioridazine HCI tablets for its potential use in managing bipolar disorder.

Understanding the market developments for Thioridazine HCI tablets requires an in-depth look at industry trends and targeted applications. Thioridazine HCI, an antipsychotic medication, has undergone significant expansion due to advancements in mental health treatment protocols.

Impact of Industry Transitions on the Thioridazine Hci Tablets Market

As a core segment of the Pharmaceutical industry, the Thioridazine Hci Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Shifts in Prescribing Practices and Expansion of Telemedicine have redefined priorities across the Pharmaceutical sector, influencing how the Thioridazine Hci Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Shifts in Prescribing Practices:

Recent years have seen considerable changes in the way Thioridazine HCI tablets are prescribed. Influenced by a growing understanding of mental health conditions, physicians now lean more towards a personalized approach in prescribing Thioridazine HCI tablets. This shift has increased the need for pharmaceutical companies to provide comprehensive patient guidance on dosage and side effects, for optimal health outcomes. This change in prescribing practices has had a profound effect on the way Thioridazine HCI tablets are marketed, highlighting the continuous adaptation the industry is undergoing.

2

Expansion of Telemedicine:

The COVID19 pandemic has significantly influenced the healthcare landscape, fostering the rapid expansion of telemedicine. This shift has implications for the Thioridazine HCI tablets market. Remote consultations and eprescriptions now cater to patient needs, even in geographically distant locations. This has ensured uninterrupted access to Thioridazine HCI tablets for patients grappling with mental health conditions, augmenting its foothold and reach within the industry.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Thioridazine Hci Tablets market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Growing Demand for Effective Antipsychotic Medication

A rise in cases of mental disorders and the growing awareness around mental health globally are also contributing to the increasing demand for effective antipsychotic medications such as Thioridazine HCI tablets. With its proven efficacy against certains of schizophrenia, Thioridazine HCI tablets are also envisaged to witness a surge in demand, supported by their ability to regulate mood among patients exhibiting severe mental health challenges.
Thioridazine HCI, as a generic medication, provides an affordable solution for patients seeking cost-effective mental health care. The trend for affordable pricing strategies in the global pharmaceutical market makes Thioridazine HCI tablets a preferred choice for many. This phenomenon, coupled with the expanding healthcare insurance coverage, is also predicted to fuel the growth of the Thioridazine HCI tablet market in the forthcoming years.

Restraint: Regulatory Constraints

The market for Thioridazine HCI tablets faces significant regulatory challenges. In many regions worldwide, this medication requires stringent approvals by health regulatory bodies, leading to delays in market entry. Factors such as stringent post-marketing surveillance, the necessity for continuous pharmacovigilance, as well as onerous requirements for the generation and maintenance of comprehensive clinical data can diminish the speed of production and distribution of Thioridazine HCI tablets. This can significantly abate market demand and dynamics.

Challenge: Declining Prescription Rates

Despite the efficacy of Thioridazine HCI tablets in treating severe mental disorders, the tablets potential side effects have led to the decline in prescription rates. Medical practitioners often consider Thioridazine HCI as a second-line treatment, opting for alternative pharmaceuticals with lesser side effects where possible. This trend affects the market demand negatively, suppressing growth dynamics for Thioridazine HCI tablets.

Supply Chain Landscape

API Production

BASF SE

Pfizer Inc

Formulation & Tablet Manufacturing

AstraZeneca PLC

GlaxoSmithKline PLC

Packaging & Labelling
Amcor Ltd / CCL Industries Inc
Distribution & Retail
API Production

BASF SE

Pfizer Inc

Formulation & Tablet Manufacturing

AstraZeneca PLC

GlaxoSmithKline PLC

Packaging & Labelling

Amcor Ltd

CCL Industries Inc

Distribution & Retail
Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Schizophrenia Treatment
Pharmaceuticals
Teva Pharmaceuticals
Focused on innovative research and development of antipsychotic drugs
Manic Depression Treatment
Pharmaceuticals
Johnson & Johnson
Incorporate latest methodologies and advances in their drug production process for efficient outcome
Anti-nausea Treatment
Pharmaceuticals
Novartis Pharmaceuticals
Leveraging patient-centric drug formulation techniques and quality control practices
Behavioural disorder Treatment
Pharmaceuticals
Eli Lilly and Company
Implementing advanced technological solutions to enhance drug efficiency and patient adherence.

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Thioridazine Hci Tablets market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Thioridazine Hci Tablets in Treatment of Behavioral Problems in Children, Use in Psychoactive Drug Therapy and Management of Schizophrenia

Treatment of Behavioral Problems in Children

Thioridazine HCI tablets have also found application in the treatment of behavioral disorders in children. The medication is used to manage severe behavioral problems such as combativeness, impulsiveness and hyperactivity in children when no other treatments have been effective.

Use in Psychoactive Drug Therapy

As a psychoactive drug, Thioridazine HCI tablets are also used in psychotherapy to control severe anxiety and agitation. The drug operates by decreasing abnormal excitement in the brain, thus providing a calming effect on patients. One unique advantage of Thioridazine HCI in psychoactive drug therapy is its ability to achieve significant therapeutic effects within a relatively short period of time, thereby enhancing patient comfort and well-being. These unique features have supported its strong market position in psychoactive drug therapy.

Management of Schizophrenia

Thioridazine HCI tablets are frequently utilized in the management of schizophrenia, a chronic and severe mental disorder that affects a persons thinking, feeling, and behavior. This antipsychotic medication works by helping restore the balance of certain natural substances in the brain. Uniquely advantageous for its efficacy and relatively low cost, Thioridazine HCI has been a staple in psychiatric care for many years. As a top player within this application, Thioridazine HCI has a strong market position due to its widespread acceptance among healthcare professionals.

Thioridazine Hci Tablets vs. Substitutes:
Performance and Positioning Analysis

Thioridazine HCI tablets hold a strong market position, offering potent antipsychotic benefits with fewer side-effects compared to alternatives. Rapid adoption in the healthcare industry indicates promising growth potential. These Alternatives specially Haloperidol Tablets has experienced a rapid growth as detailed in our latest report.

Thioridazine Hci Tablets
  • Haloperidol Tablets /
  • Chlorpromazine hydrochloride tablets /
  • Loxapine
    Effective control of schizophenic disorders, management of symptoms associated with psychotic disorders
    Potential for severe cardiac side effects, risk of tardive dyskinesia
    Effective in mitigating symptoms of schizophrenia, typically more affordable than Thioridazine HCI tablets
    Potential for serious side effects, risk of long-term health implications

Thioridazine Hci Tablets vs. Substitutes:
Performance and Positioning Analysis

Thioridazine Hci Tablets

  • Effective control of schizophenic disorders, management of symptoms associated with psychotic disorders
  • Potential for severe cardiac side effects, risk of tardive dyskinesia

Haloperidol Tablets / Chlorpromazine hydrochloride tablets / Loxapine

  • Effective in mitigating symptoms of schizophrenia, typically more affordable than Thioridazine HCI tablets
  • Potential for serious side effects, risk of long-term health implications

Thioridazine HCI tablets hold a strong market position, offering potent antipsychotic benefits with fewer side-effects compared to alternatives. Rapid adoption in the healthcare industry indicates promising growth potential. These Alternatives specially Haloperidol Tablets has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Thioridazine Hci Tablets market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Thioridazine Hci Tablets across Schizophrenia Treatment and Off-Label Usage Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Novartis Pharmaceuticals, Teva Pharmaceutical Industries, and Merck & Co. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including API Production, Formulation & Tablet Manufacturing, and Packaging & Labelling. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Thioridazine Hci Tablets segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning API Production (BASF SE, Pfizer Inc), Formulation & Tablet Manufacturing (AstraZeneca PLC, GlaxoSmithKline PLC), and Packaging & Labelling. Our parallel substitute analysis examines Haloperidol Tablets, Chlorpromazine hydrochloride tablets, and Loxapine, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Novartis Pharmaceuticals, Teva Pharmaceutical Industries, and Merck & Co., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Thioridazine Hci Tablets market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Thioridazine Hci Tablets Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 610 million
Revenue Forecast in 2034USD 1.14 billion
Growth RateCAGR of 7.2% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024569 million
Growth OpportunityUSD 572 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024569 million USD
Market Size 2027702 million USD
Market Size 2029806 million USD
Market Size 2030864 million USD
Market Size 20341.14 billion USD
Market Size 20351.22 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Form, Distribution Channel, Application, Prescription Type, Patient Population
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledNovartis Pharmaceuticals, Teva Pharmaceutical Industries, Merck & Co., Pfizer, AstraZeneca, Cannasouth Limited, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, Alembic Pharmaceuticals, Zydus Cadila and Jubilant Life Sciences.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Thioridazine Hci Tablets Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1Oral
4.2Liquid Solution
Chapter 5

Thioridazine Hci Tablets Market Size, Opportunities & Strategic Insights, by Distribution Channel

5.1Retail Pharmacy
5.2Online Pharmacy
5.3Hospital Pharmacy
5.4
Chapter 6

Thioridazine Hci Tablets Market Size, Opportunities & Strategic Insights, by Application

6.1Schizophrenia Treatment
6.2Off-Label Usage
Chapter 7

Thioridazine Hci Tablets Market Size, Opportunities & Strategic Insights, by Prescription Type

7.1Over-the-Counter
7.2Prescribed
Chapter 8

Thioridazine Hci Tablets Market Size, Opportunities & Strategic Insights, by Patient Population

8.1Adults
8.2Geriatrics
Chapter 9

Thioridazine Hci Tablets Market, by Region

9.1North America Thioridazine Hci Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Thioridazine Hci Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Thioridazine Hci Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Thioridazine Hci Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Thioridazine Hci Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Thioridazine Hci Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Novartis Pharmaceuticals
10.2.2Teva Pharmaceutical Industries
10.2.3Merck & Co.
10.2.4Pfizer
10.2.5AstraZeneca
10.2.6Cannasouth Limited
10.2.7Dr. Reddy's Laboratories
10.2.8Glenmark Pharmaceuticals
10.2.9Sun Pharmaceutical Industries
10.2.10Alembic Pharmaceuticals
10.2.11Zydus Cadila
10.2.12Jubilant Life Sciences.